Seven Talking Points At ASH 2019
Bispecifics Emerge To Challenge CAR-Ts
The tireless pace of change in hemato-oncology was showcased in Orlando.
You may also be interested in...
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.